INCLINE VILLAGE, Nevada , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) today announced that on October 27, 2017 , PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc.
- Proposal provides immediate and certain value to Neos shareholders - Proposal represents a 40% premium to Neos' October 25 closing price and provides shareholders a substantial premium - Supports PDL's specialty pharmaceutical acquisition strategy
INCLINE VILLAGE, Nev. , Oct. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2017 , on Thursday, November 2, 2017 , after market close.
INCLINE VILLAGE, Nev. , Sept. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) announced today that PDL's board of directors has authorized a new stock repurchase program to acquire up to $25 million of the Company's common stock. Purchases may be made in
INCLINE VILLAGE, Nev. , Sept. 19, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 , at
INCLINE VILLAGE, Nev. , Sept. 11, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has appointed Dominique P. Monnet to the position of president. Mr. Monnet brings over 30 years of international business experience in the biotechnology /
INCLINE VILLAGE, Nev. , Sept. 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in September. Rodman & Renshaw 19 th Annual Global Investment Conference
INCLINE VILLAGE, Nev. , July 31, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2017 , on Thursday, August 3, 2017 , after market close.
INCLINE VILLAGE, N.V. , June 5, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its subsidiary, Noden Pharma DAC ( Noden ), received a Paragraph IV Notice Letter advising that Anchen Pharmaceuticals, Inc. (Anchen) submitted an Abbreviated New Drug Application
INCLINE VILLAGE, Nev. , June 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia , the company's vice president and chief financial officer, will present at the Jefferies 2017 Healthcare Conference next week in New York .
Debt-to-Equity Conversion Plan with PDL BioPharma, Inc., Strengthens Company's Balance Sheet to Support Leadership Position in Refractive Cataract Surgery
INCLINE VILLAGE, Nev. , May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including: Total revenues of $45.4 million for the three months ended March 31, 2017 .
INCLINE VILLAGE, Nev. , April 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017 , on Wednesday, May 3, 2017 , after market close.
INCLINE VILLAGE, Nev. , April 24, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017 , the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. (" Merck ") to resolve the patent infringement
